A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

2014-08-27 03:15:18 | BioPortfolio


This was a prospective, open, non-comparative study to evaluate the safety and efficacy of rhLH (Luveris) administered subcutaneously in follicular development during ovulation induction in 30 Chinese female subjects with hypogonadotropic hypogonadism.


The objective of this study was to assess the safety and efficacy of r hLH (Luveris) administered subcutaneously in follicular development during ovulation induction. This was a prospective, open, non-comparative study to evaluate the safety and efficacy of Luveris administered subcutaneously in follicular development during ovulation induction in 30 Chinese female subjects with hypogonadotropic hypogonadism. The study was organized on an outpatient basis involving a single cycle of treatment. Prior to entry into the study, the diagnosis of hypogonadotropic hypogonadism was confirmed by history, by the presence or absence of specific clinical features and by measuring serum gonadotrophin levels. Once a subject has signed the informed consent form and after satisfying all eligibility criteria, the subject received a combination of daily injection of r hFSH 150 IU plus r hLH 75 IU. After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG. Luteal phase function was assessed by serum progesterone level determination.

A phase I sub-study to evaluate the pharmacokinetics of single subcutaneous administrations of rhLH was conducted on 24 healthy Chinese female subjects in China. The subjects were randomised into 3 groups. Each group received a single dose of 75 IU, 150 IU and 300 IU of r hLH. Blood samples were collected at predetermined intervals after the injection. Human LH serum levels were measured with the Serono MAIAclone and the in vitro bioassay MA-10. Safety was also assessed by the incidence and severity of adverse events and significant changes in laboratory values.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment






Peking Union Medical College Hospital




Merck KGaA

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:15:18-0400

Clinical Trials [110 Associated Clinical Trials listed on BioPortfolio]

Registry of Hypogonadism in Men

The primary objective of the Registry of HYpogonadism in MEn (RHYME) is to establish and maintain a large, multi-national prospective registry of male patients who have been diagnosed with...

A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism

The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.

Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirm...

Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism

The study is designed to answer the following questions: 1. Is hypogonadism a cause for the metabolic syndrome ? 2. What is the effect of testosterone replacement on the metabolic pa...

PubMed Articles [73 Associated PubMed Articles listed on BioPortfolio]

High risk of hypogonadism in young male cancer survivors.

Cancer and its treatment in childhood and young adulthood can cause hypogonadism, leading to increased risk of long term morbidity and mortality. The aim of this study was to evaluate the risk of pres...

Oxytocin intranasal administration as a new hope for hypogonadotropic hypogonadism patients.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism which also known as secondary or central hypogonadism. Congenital HH can occur due to defect in gonadotropin releasing hormone (GnRH) neuro...

Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.

Men with primary or secondary hypogonadism (HG) prescribed testosterone therapy (TTh) who terminate treatment early might not obtain the benefit of symptom relief.

Molecular genetic and clinical delineation of 22 patients with congenital hypogonadotropic hypogonadism.

Congenital hypogonadotropic hypogonadism (CHH) is classified as Kallmann syndrome (KS) with anosmia/hyposmia or normosmic (n)CHH. Here, we investigated the genetic causes and phenotype-genotype correl...

Homozygous nonsense mutation Trp28X in the LHB gene causes male hypogonadism.

The purpose of this study was to investigate a novel mutation in the luteinizing hormone beta-subunit (LHB) gene in one male patient with hypogonadism due to selective luteinizing hormone (LH) deficie...

Medical and Biotech [MESH] Definitions

Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).

An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.

A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with ANEMIA, short stature, HYPOGONADISM, impaired WOUND HEALING, and geophagia. It is known by the symbol Zn.

An autosomal recessive syndrome occurring principally in females, characterized by the presence of reticulated, atrophic, hyperpigmented, telangiectatic cutaneous plaques, often accompanied by juvenile cataracts, saddle nose, congenital bone defects, disturbances in the growth of HAIR; NAILS; and TEETH; and HYPOGONADISM.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

More From BioPortfolio on "A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism"

Quick Search


Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Searches Linking to this Trial